{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:30:55Z","timestamp":1762299055698,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40266-019-00691-8","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T02:05:02Z","timestamp":1562810702000},"page":"853-862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis: A Post-Hoc Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"36","author":[{"given":"Christopher J.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Roshak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack F.","family":"Bukowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazhar","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Borlenghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Curiale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1186-0669","authenticated-orcid":false,"given":"Heather","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"key":"691_CR1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40273-014-0174-6","volume":"32","author":"T Uhlig","year":"2014","unstructured":"Uhlig T, Moe RH, Kvien TK. The burden of disease in rheumatoid arthritis. Pharmacoeconomics. 2014;32:841\u201351.","journal-title":"Pharmacoeconomics"},{"key":"691_CR2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094\u2013108.","journal-title":"Lancet"},{"key":"691_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.semarthrit.2006.08.006","volume":"36","author":"Y Alamanos","year":"2006","unstructured":"Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36:182\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"691_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40266-013-0122-8","volume":"30","author":"M Soubrier","year":"2013","unstructured":"Soubrier M, Tatar Z, Couderc M, Mathieu S, Dubost JJ. Rheumatoid arthritis in the elderly in the era of tight control. Drugs Aging. 2013;30:863\u20139.","journal-title":"Drugs Aging"},{"key":"691_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00296-002-0251-6","volume":"23","author":"IA Papadopoulos","year":"2003","unstructured":"Papadopoulos IA, Katsimbri P, Alamanos Y, Voulgari PV, Drosos AA. Early rheumatoid arthritis patients: relationship of age. Rheumatol Int. 2003;23:70\u20134.","journal-title":"Rheumatol Int"},{"key":"691_CR6","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1316\u201322.","journal-title":"Ann Rheum Dis"},{"key":"691_CR7","unstructured":"World Health Organization. Proposed working definition of an older person in Africa for the MDS Project. 2002. http:\/\/www.who.int\/healthinfo\/survey\/ageingdefnolder\/en\/ . Accessed 04 Sept 2018."},{"key":"691_CR8","doi-asserted-by":"publisher","first-page":"e33559","DOI":"10.1371\/journal.pone.0033559","volume":"7","author":"C Konrat","year":"2012","unstructured":"Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One. 2012;7:e33559.","journal-title":"PLoS One."},{"key":"691_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/RHU.0b013e3181fe8b37","volume":"16","author":"M Ogasawara","year":"2010","unstructured":"Ogasawara M, Tamura N, Onuma S, Kusaoi M, Sekiya F, Matsudaira R, et al. Observational cross-sectional study revealing less aggressive treatment in Japanese elderly than nonelderly patients with rheumatoid arthritis. J Clin Rheumatol. 2010;16:370\u20134.","journal-title":"J Clin Rheumatol."},{"key":"691_CR10","doi-asserted-by":"publisher","first-page":"e002468","DOI":"10.1136\/bmjopen-2012-002468","volume":"3","author":"B Ng","year":"2013","unstructured":"Ng B, Chu A, Khan MM. A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers. BMJ Open. 2013;3:e002468.","journal-title":"BMJ Open"},{"key":"691_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/rheumatology\/ket399","volume":"53","author":"RB Mueller","year":"2014","unstructured":"Mueller RB, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, von Kempis J. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. Rheumatology (Oxford). 2014;53:671\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"691_CR12","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar4540","volume":"16","author":"L Innala","year":"2014","unstructured":"Innala L, Berglin E, M\u00f6ller B, Ljung L, Smedby T, S\u00f6dergren A, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2014;16:R94.","journal-title":"Arthritis Res Ther"},{"key":"691_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jbspin.2014.10.012","volume":"82","author":"C Lahaye","year":"2015","unstructured":"Lahaye C, Tatar Z, Dubost JJ, Soubrier M. Overview of biologic treatments in the elderly. Jt Bone Spine. 2015;82:154\u201360.","journal-title":"Jt Bone Spine"},{"key":"691_CR14","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/rheumatology\/kel144","volume":"45","author":"L Fraenkel","year":"2006","unstructured":"Fraenkel L, Rabidou N, Dhar R. Are rheumatologists\u2019 treatment decisions influenced by patients\u2019 age? Rheumatology (Oxford). 2006;45:1555\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"691_CR15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/acr.20123","volume":"62","author":"W Kievit","year":"2010","unstructured":"Kievit W, van Hulst L, van Riel P, Fraenkel L. Factors that influence rheumatologists\u2019 decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis. Arthritis Care Res (Hoboken). 2010;62:842\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"691_CR16","unstructured":"United Nations. Ageing. 2017. http:\/\/www.un.org\/en\/sections\/issues-depth\/ageing\/index.html . Accessed 18 Dec 2018."},{"key":"691_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12891-016-1038-3","volume":"17","author":"M van Onna","year":"2016","unstructured":"van Onna M, Boonen A. The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskelet Disord. 2016;17:184.","journal-title":"BMC Musculoskelet Disord"},{"key":"691_CR18","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00296-017-3749-7","volume":"37","author":"K Pavelka","year":"2017","unstructured":"Pavelka K, Akko\u00e7 N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, et al. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. Rheumatol Int. 2017;37:1469\u201379.","journal-title":"Rheumatol Int"},{"key":"691_CR19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","volume":"381","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381:918\u201329.","journal-title":"Lancet"},{"key":"691_CR20","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","volume":"371","author":"P Emery","year":"2014","unstructured":"Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014;371:1781\u201392.","journal-title":"N Engl J Med"},{"key":"691_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/annrheumdis-2013-205079","volume":"74","author":"MM Ward","year":"2015","unstructured":"Ward MM, Guthrie LC, Alba MI. Clinically important changes in individual and composite measures of rheumatoid arthritis activity. Ann Rheum Dis. 2015;74:1691\u20136.","journal-title":"Ann Rheum Dis"},{"key":"691_CR22","unstructured":"European Medicines Agency. Enbrel procedural steps taken and scientific information after the authorisation. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/enbrel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf . Accessed 12 July 2018."},{"key":"691_CR23","unstructured":"European Medicines Agency. Enbrel Summary of Product Characteristics. 2018. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000262\/WC500027361.pdf . Accessed 12 July 2018."},{"key":"691_CR24","volume-title":"Guidelines for preparing core clinical-safety information on drugs","author":"CIOMS Working Group III","year":"1995","unstructured":"CIOMS Working Group III. Guidelines for preparing core clinical-safety information on drugs. Geneva: CIOMS; 1995."},{"key":"691_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-015-0501-8","volume":"17","author":"AM Orbai","year":"2015","unstructured":"Orbai AM, Bingham CO 3rd. Patient reported outcomes in rheumatoid arthritis clinical trials. Curr Rheumatol Rep. 2015;17:28.","journal-title":"Curr Rheumatol Rep"},{"key":"691_CR26","first-page":"234","volume":"33","author":"JM Bathon","year":"2006","unstructured":"Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006;33:234\u201343.","journal-title":"J Rheumatol"},{"key":"691_CR27","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/art.22688","volume":"57","author":"S Genevay","year":"2007","unstructured":"Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;57:679\u201385.","journal-title":"Arthritis Rheum"},{"key":"691_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12016-009-8142-1","volume":"38","author":"M Filippini","year":"2010","unstructured":"Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010;38:90\u20136.","journal-title":"Clin Rev Allergy Immunol"},{"key":"691_CR29","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1136\/ard.2008.094730","volume":"68","author":"BJ Radovits","year":"2009","unstructured":"Radovits BJ, Kievit W, Fransen J, van de Laar MA, Jansen TL, van Riel PL, et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1470\u20133.","journal-title":"Ann Rheum Dis"},{"key":"691_CR30","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/rheumatology\/kep291","volume":"48","author":"MD K\u00f6ller","year":"2009","unstructured":"K\u00f6ller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford). 2009;48:1575\u201380.","journal-title":"Rheumatology (Oxford)"},{"key":"691_CR31","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/art.20048","volume":"50","author":"E Krishnan","year":"2004","unstructured":"Krishnan E, Sokka T, H\u00e4kkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum. 2004;50:953\u201360.","journal-title":"Arthritis Rheum"},{"key":"691_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrrheum.2013.92","volume":"9","author":"AM Boots","year":"2013","unstructured":"Boots AM, Maier AB, Stinissen P, Masson P, Lories RJ, De Keyser F. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:604\u201313.","journal-title":"Nat Rev Rheumatol"},{"key":"691_CR33","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13075-016-1176-x","volume":"18","author":"J Humphreys","year":"2016","unstructured":"Humphreys J, Hyrich K, Symmons D. What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? Arthritis Res Ther. 2016;18:282.","journal-title":"Arthritis Res Ther."},{"key":"691_CR34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480\u20139.","journal-title":"Ann Rheum Dis"},{"key":"691_CR35","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.trci.2017.10.002","volume":"3","author":"A Judge","year":"2017","unstructured":"Judge A, Garriga C, Arden NK, Lovestone S, Prieto-Alhambra D, Cooper C, et al. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimers Dement (NY). 2017;3:612\u201321.","journal-title":"Alzheimers Dement (NY)"},{"key":"691_CR36","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1532-5415.1997.tb02968.x","volume":"45","author":"MW Rich","year":"1997","unstructured":"Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc. 1997;45:968\u201374.","journal-title":"J Am Geriatr Soc"},{"key":"691_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/clinids\/22.2.209","volume":"22","author":"KB Crossley","year":"1996","unstructured":"Crossley KB, Peterson PK. Infections in the elderly. Clin Infect Dis. 1996;22:209\u201315.","journal-title":"Clin Infect Dis"},{"key":"691_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.14336\/AD.2017.0503","volume":"8","author":"S Garcovich","year":"2017","unstructured":"Garcovich S, Colloca G, Sollena P, Andrea B, Balducci L, Cho WC, et al. Skin cancer epidemics in the elderly as an emerging issue in geriatric oncology. Aging Dis. 2017;8:643\u201361.","journal-title":"Aging Dis"},{"key":"691_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/0976-500X.110872","volume":"4","author":"DK Brahma","year":"2013","unstructured":"Brahma DK, Wahlang JB, Marak MD, Ch Sangma M. Adverse drug reactions in the elderly. J Pharmacol Pharmacother. 2013;4:91\u20134.","journal-title":"J Pharmacol Pharmacother"},{"key":"691_CR40","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","volume":"75","author":"J Zhang","year":"2016","unstructured":"Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1813\u20138.","journal-title":"Ann Rheum Dis"},{"key":"691_CR41","first-page":"1","volume":"4","author":"A Lurati","year":"2010","unstructured":"Lurati A, Marrazza M, Angela K, Scarpellini M. Safety of etanercept in elderly subjects with rheumatoid arthritis. Biologics. 2010;4:1\u20134.","journal-title":"Biologics"},{"key":"691_CR42","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6\u00a0months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50:124\u201331.","journal-title":"Rheumatology (Oxford)"},{"key":"691_CR43","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/art.22600","volume":"56","author":"S Schneeweiss","year":"2007","unstructured":"Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:1754\u201364.","journal-title":"Arthritis Rheum"},{"key":"691_CR44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00296-016-3631-z","volume":"37","author":"H Kawashima","year":"2017","unstructured":"Kawashima H, Kagami SI, Kashiwakuma D, Takahashi K, Yokota M, Furuta S, et al. Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. Rheumatol Int. 2017;37:369\u201376.","journal-title":"Rheumatol Int"},{"key":"691_CR45","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/rheumatology\/ker281","volume":"50","author":"N Busquets","year":"2011","unstructured":"Busquets N, Tomero E, Descalzo M\u00c1, Ponce A, Ortiz-Santamaria V, Sur\u00eds X, et al. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology (Oxford). 2011;50:1999\u20132004.","journal-title":"Rheumatology (Oxford)"},{"key":"691_CR46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12891-016-1185-6","volume":"17","author":"SK Cho","year":"2016","unstructured":"Cho SK, Sung YK, Kim D, Won S, Choi CB, Kim TH, et al. Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016;17:333.","journal-title":"BMC Musculoskelet Disord"},{"key":"691_CR47","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.3899\/jrheum.160012","volume":"43","author":"A Murota","year":"2016","unstructured":"Murota A, Kaneko Y, Yamaoka K, Takeuchi T. Safety of biologic agents in elderly patients with rheumatoid arthritis. J Rheumatol. 2016;43:1984\u20138.","journal-title":"J Rheumatol"},{"key":"691_CR48","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/107327481402100305","volume":"21","author":"AC Denson","year":"2014","unstructured":"Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control. 2014;21:209\u201314.","journal-title":"Cancer Control"},{"key":"691_CR49","doi-asserted-by":"publisher","first-page":"e0155948","DOI":"10.1371\/journal.pone.0155948","volume":"11","author":"FT Bourgeois","year":"2016","unstructured":"Bourgeois FT, Olson KL, Tse T, Ioannidis JP, Mandl KD. Prevalence and characteristics of interventional trials conducted exclusively in elderly persons: a cross-sectional analysis of registered clinical trials. PLoS One. 2016;11:e0155948.","journal-title":"PLoS One"},{"key":"691_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/RHU.0000000000000152","volume":"20","author":"WJ Martin","year":"2014","unstructured":"Martin WJ, Shim M, Paulus HE, Chaudhari S, Feng J, Elashoff D, et al. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry. J Clin Rheumatol. 2014;20:301\u20135.","journal-title":"J Clin Rheumatol"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-019-00691-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T12:32:12Z","timestamp":1610368332000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-019-00691-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1007\/s40266-019-00691-8","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"type":"print","value":"1170-229X"},{"type":"electronic","value":"1179-1969"}],"subject":[],"published":{"date-parts":[[2019,7,11]]},"assertion":[{"value":"11 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Pfizer. Medical writing support was provided by Lorna Forse, PhD, of Engage Scientific Solutions and was funded by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Professor Edwards has received honoraria for advisory boards and speakers\u2019 bureau and research support from AbbVie, BMS, Biogen, Celgene, Fresenius, Janssen, Lilly, Mundipharma, Pfizer, MSD, Novartis, Roche, Samsung, Sanofi, and UCB. Ms. Roshak was an employee of Pfizer at the time of data generation and manuscript initiation. Dr. Thakur is an employee of RegSafe Consulting Limited and was contracted by Pfizer in connection with the development of the manuscript. Mr. Pedersen, Dr. Borlenghi, and Dr. Curiale are employees of and own stock in Pfizer. Dr. Bukowski, Ms. Jones, and Dr. Marshall were employees of Pfizer at the time of data generation and manuscript development and own stock in Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As a non-interventional study, ethical approval was not required for this analysis. This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Upon request, and subject to certain criteria, conditions, and exceptions (seefor more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the USA and\/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24\u00a0months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}}]}}